Could a cancer drug slow Alzheimer's? new trial aims to find out.
Disease control
Not yet recruiting
This phase 3 trial tests whether masitinib, a drug that targets immune cells in the brain, can help people with mild Alzheimer's when added to their current treatment. About 600 participants will receive either masitinib or a placebo for 24 weeks. The study measures changes in th…
Phase: PHASE3 • Sponsor: AB Science • Aim: Disease control
Last updated Apr 26, 2026 20:01 UTC